학술논문

Blood first line ready screening trial ( B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic
Document Type
Journal
Source
ANNALS OF ONCOLOGY; SEP 2017, 28 2p. Supplement: 5
Subject
Language
English
ISSN
15698041